De novo autoimmune connective tissue disease and mortality in patients treated with anti-PD-1 and anti-PD-L1 therapy: a population-level cohort study.

Using a population-level cohort analysis, our study demonstrates that though rare, de novo autoimmune cutaneous connective tissue disorders (AiCTD) in the setting of immune checkpoint inhibitors (ICI) are not associated with a greater risk of mortality and are overall approaching a statistically significant decrease in mortality when compared to ICI-treated patients without cutaneous immune-related adverse events. These findings are significant and highly relevant to dermatologists and oncologists caring for ICI recipients as it adds to the limited information on development of cutaneous AiCTD following ICI administration, for which enhanced understanding is critical to improving the care for this challenging patient population.